Roche Holding Company Profile (NASDAQ:RHHBY)

About Roche Holding (NASDAQ:RHHBY)

Roche Holding logoRoche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: NASDAQ:RHHBY
  • CUSIP: N/A
  • Web: www.roche.com
Average Prices:
  • 50 Day Moving Avg: $31.62
  • 200 Day Moving Avg: $32.24
  • 52 Week Range: $25.25 - $36.82
P/E:
  • Trailing P/E Ratio: 21.49
  • Foreward P/E Ratio: 15.74
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $56.87 billion
  • Price / Sales: N/A
  • Book Value: $3.51 per share
  • Price / Book: 9.10
Dividend:
  • Dividend Yield: 3.2%
Profitability:
  • EBIDTA: $22.47 billion
  • Net Margins: 21.17%
  • Return on Equity: 46.76%
  • Return on Assets: 14.96%
Misc:
  • Average Volume: 1.31 million shs.
 

Frequently Asked Questions for Roche Holding (NASDAQ:RHHBY)

What is Roche Holding's stock symbol?

Roche Holding trades on the NASDAQ under the ticker symbol "RHHBY."

Where is Roche Holding's stock going? Where will Roche Holding's stock price be in 2017?

10 brokerages have issued 12 month price objectives for Roche Holding's stock. Their forecasts range from $38.00 to $38.00. On average, they anticipate Roche Holding's stock price to reach $38.00 in the next twelve months. View Analyst Ratings for Roche Holding.

Who are some of Roche Holding's key competitors?

Who are Roche Holding's key executives?

Roche Holding's management team includes the folowing people:

  • Severin Schwan, Chairman of the Corporate Executive Committee, Chief Executive Officer, Executive Director
  • Alan Hippe, Member of the Corporate Executive Committee, Chief Financial Officer, Information Technology Officer
  • Stephan Feldhaus, Member of the Enlarged Corporate Executive Committee, Head Group Communications
  • Sophie Kornowski-Bonnet, Member of the Enlarged Corporate Executive Committee, Head Roche Partnering
  • Osamu Nagayama, Member of the Enlarged Corporate Executive Committee, Chairman and Chief Executive Officer Chugai
  • John C. Reed M.D., Ph.D., Member of the Enlarged Corporate Executive Committee, Head of Roche Pharma Research & Early Development
  • Michael David Varney, Member of the Enlarged Corporate Executive Committee, Head Genetech Research and Early Development
  • Cristina A. Wilbur, Member of the Executive Committee, Head Group Human Resources
  • Urs Jaisli, Chief Compliance Officer
  • Gottlieb A. Keller, Member of the Group Executive Committee, General Counsel, Secretary to the Board of Directors

Who owns Roche Holding stock?

Roche Holding's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Fisher Asset Management LLC (0.00%), Parametric Portfolio Associates LLC (0.00%), Schafer Cullen Capital Management Inc. (0.00%), Bristol John W & Co. Inc. NY (0.00%), Capital Counsel LLC NY (0.00%) and Riverbridge Partners LLC (0.00%). View Institutional Ownership Trends for Roche Holding.

Who sold Roche Holding stock? Who is selling Roche Holding stock?

Roche Holding's stock was sold by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC, Boston Common Asset Management LLC, Blair William & Co. IL, Kornitzer Capital Management Inc. KS, Thomas White International Ltd., Moody Lynn & Lieberson LLC, Riverbridge Partners LLC and Sit Investment Associates Inc.. View Insider Buying and Selling for Roche Holding.

Who bought Roche Holding stock? Who is buying Roche Holding stock?

Roche Holding's stock was purchased by a variety of institutional investors in the last quarter, including Parametric Portfolio Associates LLC, Capital Counsel LLC NY, Bristol John W & Co. Inc. NY, Icon Advisers Inc. Co., Beach Investment Management LLC., Schafer Cullen Capital Management Inc., Lenox Wealth Management Inc. and Pacer Advisors Inc.. View Insider Buying and Selling for Roche Holding.

How do I buy Roche Holding stock?

Shares of Roche Holding can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Roche Holding's stock price today?

One share of Roche Holding stock can currently be purchased for approximately $31.95.


MarketBeat Community Rating for Roche Holding (NASDAQ RHHBY)
Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  63 (Vote Outperform)
Underperform Votes:  67 (Vote Underperform)
Total Votes:  130
MarketBeat's community ratings are surveys of what our community members think about Roche Holding and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Roche Holding (NASDAQ:RHHBY) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 5 Hold Ratings, 4 Buy Ratings
Consensus Rating:Hold (Score: 2.30)
Consensus Price Target: $38.00 (18.94% upside)

Analysts' Ratings History for Roche Holding (NASDAQ:RHHBY)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/19/2017Cowen and CompanyReiterated RatingBuy$38.00LowView Rating Details
7/26/2017Morgan StanleyReiterated RatingOverweight -> Equal WeightHighView Rating Details
7/7/2017Deutsche Bank AGDowngradeBuy -> HoldLowView Rating Details
6/30/2017Societe GeneraleDowngradeBuy -> HoldLowView Rating Details
6/20/2017BNP ParibasReiterated RatingOutperform -> NeutralLowView Rating Details
4/7/2017HSBC Holdings plcDowngradeHold -> ReduceLowView Rating Details
3/9/2017Liberum CapitalInitiated CoverageHold -> HoldLowView Rating Details
3/7/2017Barclays PLCInitiated CoverageOverweightN/AView Rating Details
2/19/2017Jefferies Group LLCReiterated RatingBuyN/AView Rating Details
12/7/2016Sanford C. BernsteinReiterated RatingOverweightN/AView Rating Details
8/3/2016Citigroup Inc.Reiterated RatingBuyN/AView Rating Details
(Data available from 9/22/2015 forward)

Earnings

Earnings History for Roche Holding (NASDAQ:RHHBY)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Roche Holding (NASDAQ:RHHBY)
Current Year EPS Consensus Estimate: $1.91 EPS
Next Year EPS Consensus Estimate: $2.03 EPS

Dividends

Dividend History for Roche Holding (NASDAQ:RHHBY)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Roche Holding (NASDAQ:RHHBY)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Roche Holding (NASDAQ:RHHBY)
Latest Headlines for Roche Holding (NASDAQ:RHHBY)
Source:
DateHeadline
seekingalpha.com logoIs This The Best Oncology Play In The Market? - Seeking Alpha
seekingalpha.com - September 19 at 7:09 AM
nasdaq.com logoRoche's (RHHBY) Tecentriq Studies Put on Partial Hold by FDA - Nasdaq
www.nasdaq.com - September 19 at 7:09 AM
nasdaq.com logoRoche (RHHBY) Announces Data on Respiratory Drug Esbriet - Nasdaq
www.nasdaq.com - September 13 at 8:41 PM
finance.yahoo.com logoRoche (RHHBY) Announces Data on Respiratory Drug Esbriet
finance.yahoo.com - September 13 at 8:41 PM
seekingalpha.com logoCompare 4 Companies' Cystic Fibrosis Drugs: Roche, Protalix, Vertex And Galopagos
seekingalpha.com - September 13 at 3:41 PM
finance.yahoo.com logoArray's NDAs for Melanoma Combo Accepted for Review by FDA
finance.yahoo.com - September 13 at 3:41 PM
finance.yahoo.com logoNektar (NKTR) Starts PROPEL Combo Study for Cancer Candidate
finance.yahoo.com - September 13 at 3:41 PM
seekingalpha.com logoCompare 4 Companies' Cystic Fibrosis Drugs: Roche, Protalix, Vertex And Galapagos
seekingalpha.com - September 13 at 8:23 AM
seekingalpha.com logoRoche's Zelboraf flunks late-stage melanoma study - Seeking Alpha
seekingalpha.com - September 12 at 9:14 AM
benzinga.com logoThis Drug Could Treat Suicidal Depression And PTSD, An ... - Benzinga
www.benzinga.com - September 8 at 7:41 AM
americanbankingnews.com logoRoche Holding Ltd. (RHHBY) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - September 6 at 5:16 PM
nasdaq.com logoRoche's Gazyva Gets Priority Review for Follicular Lymphoma - Nasdaq
www.nasdaq.com - August 29 at 3:16 PM
marketwatch.com logoReps. Cummings, Welch to launch investigation into multiple sclerosis drug prices
www.marketwatch.com - August 17 at 4:06 PM
americanbankingnews.com logoRoche Holding Ltd. (NASDAQ:RHHBY) Earns "Buy" Rating from Cowen and Company
www.americanbankingnews.com - August 14 at 4:18 PM
americanbankingnews.com logoRoche Holding Ltd. (RHHBY) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - August 12 at 2:50 PM
seekingalpha.com logoDoes Roche Have The Hemophilia X Factor? - Seeking Alpha
seekingalpha.com - August 10 at 7:22 AM
finance.yahoo.com logoROCHE LOSS NOTICE: Rosen Law Firm Reminds Roche Holding AG Investors of Important Deadline in First Filed Class Action – RHHBY
finance.yahoo.com - August 4 at 7:35 AM
finance.yahoo.com logo4-DAY DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Roche Holding AG and Reminds Investors with Losses Exceeding $100,000 to Contact the Firm
finance.yahoo.com - August 4 at 7:35 AM
finance.yahoo.com logoDeadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of the August 7, 2017 Deadline in the Class Action Lawsuit Against Roche Holding AG
finance.yahoo.com - August 4 at 7:35 AM
finance.yahoo.com logoFDA Grants Genentech’s Alecensa Priority Review for Initial Treatment of People with ALK-Positive Lung Cancer
finance.yahoo.com - August 3 at 1:55 AM
globenewswire.com logoDEADLINE ALERT: Brower Piven Reminds Investors Of Upcoming Deadline And Encourages Shareholders Who Have ... - GlobeNewswire (press release)
globenewswire.com - August 2 at 7:10 AM
finance.yahoo.com logoIMMINENT ROCHE LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Roche Holding AG To Contact The Firm
finance.yahoo.com - July 25 at 5:23 AM
finance.yahoo.com logoTWO WEEK DEADLINE: Lundin Law PC Announces Securities Class Action Lawsuit against Roche Holding AG and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - July 25 at 5:23 AM
finance.yahoo.com logoSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Roche Holding AG. (RHHBY) and Lead Plaintiff Deadline: August 7, 2017
finance.yahoo.com - July 20 at 3:48 PM
finance.yahoo.com logoEQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Roche Holding AG of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 7, 2017 - RHHBY
finance.yahoo.com - July 20 at 3:48 PM
finance.yahoo.com logo5 New Breast Cancer Treatments From Lilly, Novartis and Pfizer That Could Double Sales by 2021
finance.yahoo.com - July 20 at 3:48 PM
finance.yahoo.com logoDEADLINE ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Roche Holding AG and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - July 20 at 3:48 PM
finance.yahoo.com logoSHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Roche Holding AG. (RHHBY) and Lead Plaintiff Deadline: August 7, 2017
finance.yahoo.com - July 19 at 7:15 AM
finance.yahoo.com logoDEADLINE APPROACHING: Lundin Law PC Announces Securities Class Action Lawsuit against Roche Holding AG and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - July 19 at 7:15 AM
finance.yahoo.com logoPoor test results for Roche cloud growth prospects
finance.yahoo.com - July 19 at 7:15 AM
americanbankingnews.com logoRoche Holding Ltd. (RHHBY) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - July 18 at 5:31 PM
nasdaq.com logoBioLineRx/Roche Scan BL-8040-Tecentriq for Pancreatic Cancer - Nasdaq
www.nasdaq.com - July 11 at 9:19 PM
nasdaq.com logoRoche (RHHBY) Announces Positive Data on Hemophilia A Drug - Nasdaq
www.nasdaq.com - July 11 at 9:19 PM
zacks.com logoBioLineRx/Roche Scan BL-8040-Tecentriq for Pancreatic Cancer
www.zacks.com - July 11 at 4:17 PM
finance.yahoo.com logoSHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Roche Holding AG. (RHHBY) & Lead Plaintiff Deadline - August 7, 2017
finance.yahoo.com - July 11 at 4:16 PM
finance.yahoo.com logoEQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Roche Holding AG and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - July 11 at 4:16 PM
globenewswire.com logoRosen Law Firm Reminds Roche Holding AG Investors of Important Deadline in First Filed Class Action – RHHBY - GlobeNewswire (press release)
globenewswire.com - July 8 at 2:01 PM
americanbankingnews.com logoDeutsche Bank AG Lowers Roche Holding Ltd. (RHHBY) to Hold
www.americanbankingnews.com - July 8 at 12:22 AM
nasdaq.com logoRoche's (RHHBY) Leukemia Drug Gets Prime Status in EU - Nasdaq
www.nasdaq.com - July 1 at 7:01 AM
seekingalpha.com logoRoche acquires diabetes tracking app developer - Seeking Alpha
seekingalpha.com - July 1 at 7:01 AM
americanbankingnews.com logoRoche Holding Ltd. (RHHBY) Lowered to "Hold" at Societe Generale
www.americanbankingnews.com - June 30 at 1:20 PM
prnewswire.com logoINVESTOR ALERT: Monteverde & Associates PC Invites Roche ... - PR Newswire (press release)
www.prnewswire.com - June 30 at 6:15 AM
finance.yahoo.com logoRoche expands Harmony® Prenatal Test to include 22q11.2 deletion testing
finance.yahoo.com - June 29 at 6:33 AM
finance.yahoo.com logoThe Klein Law Firm Notifies Investors of a Class Action Filed on Behalf of Roche Holding AG Shareholders and a Lead Plaintiff Deadline of August 7, 2017 (RHHBY)
finance.yahoo.com - June 29 at 6:33 AM
globenewswire.com logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Roche Holding AG of a Class Action Lawsuit ... - GlobeNewswire (press release)
globenewswire.com - June 28 at 8:44 AM
globenewswire.com logoRHHBY SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action Involving ... - GlobeNewswire (press release)
globenewswire.com - June 28 at 8:44 AM
finance.yahoo.com logoRHHBY SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action Involving Roche Holding AG and a Lead Plaintiff Deadline of August 7, 2017
finance.yahoo.com - June 27 at 7:35 PM
finance.yahoo.com logoIMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Roche Holding AG and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - June 27 at 7:35 PM
finance.yahoo.com logoGenentech’s Emicizumab Showed Positive Results in Phase III Studies (HAVEN 1 and HAVEN 2) in Hemophilia A With Inhibitors
finance.yahoo.com - June 27 at 7:48 AM
finance.yahoo.com logoRoche says new haemophilia drug cuts bleed rate by 87 pct
finance.yahoo.com - June 27 at 7:48 AM

Social

Chart

Roche Holding (RHHBY) Chart for Friday, September, 22, 2017

This page was last updated on 9/22/2017 by MarketBeat.com Staff